Business
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI
Companies to Jointly Invest up to $1 Billion Over Five Years in Infrastructure and Research NVIDIA and Lilly NVIDIA and Eli Lilly and Company today announced a first-of-its-kind AI co-innovation lab focused on applying AI to tackle some of the most enduring challenges in the pharmaceutical industry. News Summary: NVIDIA and Lilly bring together a world-leading, multidisciplinary team of scientists, AI researchers and engineers to address the hardest problems in drug discovery.The co-innovation l
About this update from Eli Lilly And Company
[{"type":"image","alt":"NVIDIA","displaySize":"","headline":null,"caption":"NVIDIA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":223,"url":"https://media.zenfs.com/en/globenewswire.com/355d2074bfeeb36731bc01ea8e2d5ce3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xja2gkz5Lzdhv7FY6_kQlg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMxMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/355d2074bfeeb36731bc01ea8e2d5ce3","width":300,"height":223}},"lazy":false},{"type":"text","content":"Companies to Jointly Invest up to $1 Billion Over Five Years in Infrastructure and Research","length":91,"tagName":"p"},{"type":"text","content":"NVIDIA and Lilly","length":16,"tagName":"p"},{"type":"image","alt":"NVIDIA and Eli Lilly and Company today announced a first-of-its-kind AI co-innovation lab focused on applying AI to tackle some of the most enduring challenges in the pharmaceutical industry.","displaySize":"","headline":null,"caption":"NVIDIA and Eli Lilly and Company today announced a first-of-its-kind AI co-innovation lab focused on applying AI to tackle some of the most enduring challenges in the pharmaceutical industry.","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1920,"height":1080,"url":"https://media.zenfs.com/en/globenewswire.com/5e0080b8f9c1e3d09261ca3f4d7e5650"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HM7QLRwD9Fcuft7n7EssRA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5e0080b8f9c1e3d09261ca3f4d7e5650","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/HKTTQlPqDy12ifdl2kps7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/5e0080b8f9c1e3d09261ca3f4d7e5650","width":1200,"height":675}}},{"type":"text","content":"News Summary:","length":13,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"NVIDIA and Lilly bring together a world-leading, multidisciplinary team of scientists, AI researchers and engineers to address the hardest problems in drug discovery.","length":166,"tagName":"p"}]},{"val":[{"type":"text","content":"The co-innovation lab infrastructure will be built on the NVIDIA BioNeMo platform and the NVIDIA Vera Rubin architecture.","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"...